Zydus Lifesciences Ltd 2023 AR2

The report highlights Zydus Lifesciences Limited's financial and operational performance for the fiscal year 2022-23, showcasing a 14% revenue growth to ₹172.4 billion. The company made significant progress in its ESG initiatives, achieving a 20% reduction in greenhouse gas emission intensity and a 150% increase in renewable energy utilization. Zydus also advanced its innovation pipeline with key clinical trials for its NCEs, Saroglitazar and Desidustat, and launched the indigenously developed MMR vaccine in India. Additionally, the company's CSR program supported the Zydus Medical College and Hospital in Dahod, treating over 414,000 patients during the year.

Company: Zydus Lifesciences Ltd

Sector: Health Care

Country: India

Year: 2023

Type: AR2

Pages: 372

Back to company

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd 2023 Annual Report

Annual Report

The report highlights Zydus Lifesciences Limited's financial and operational performance for the fiscal year 2022-23, showcasing a 14% revenue growth to ₹172.4 billion. The company made significant progress in its ESG initiatives, achieving a 20% reduction in greenhouse gas emission intensity and a 150% increase in renewable energy utilization. Zydus also advanced its innovation pipeline with key clinical trials for its NCEs, Saroglitazar and Desidustat, and launched the indigenously developed MMR vaccine in India. Additionally, the company's CSR program supported the Zydus Medical College and Hospital in Dahod, treating over 414,000 patients during the year.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2023

Reporting Period

Apr 1, 2022 - Mar 31, 2023

Fiscal Year

2023

Type

Annual Report with Sustainability Disclosures

Language

English

Pages

 

File Size

 

Standards & Assurance

Materiality Assessment

Assurance

Assurance Provider

Assurance Standard

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 1:

Scope 2:

Scope 3:

Energy Consumption

Renewable Energy

Water Consumption

Total Waste

Women on Board

Women in Management

Workplace Fatalities

Employees